
Opinion|Videos|April 28, 2025
Clinical Manifestation of ATTR-CM and Red Flag Symptoms
Panelists discuss how recognizing key clinical manifestations and red flag symptoms, such as bilateral carpal tunnel syndrome, spinal stenosis, and trigger fingers, is critical for early diagnosis and intervention in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), particularly in those with unexplained heart failure or arrhythmias.
Advertisement
Episodes in this series

Summary for Physicians: Clinical Manifestations and Red Flag Symptoms of ATTR-CM
Clinical Manifestations of ATTR-CM:
- Cardiac symptoms:
- Heart failure (HF), often with restrictive cardiomyopathy
- Atrial arrhythmias that are resistant to ablation procedures
- Bradyarrhythmias and tachyarrhythmias
- Pacemaker dependence in advanced cases
- Extracardiac symptoms:
- Bilateral carpal tunnel syndrome (CTS): Often a key early sign of the disease
- Spinal stenosis: May cause discomfort or neurological deficits
- Trigger fingers: Common in patients with hereditary transthyretin amyloid cardiomyopathy (hATTR-CM)
- Pulmonary embolism: Can occur in advanced stages
- Electrocardiogram findings:
- May show signs of low-voltage QRS complexes, heart block, or other arrhythmias typical of restrictive cardiomyopathy
- Imaging:
- Echocardiography and cardiac MRI often show characteristic features of restrictive cardiomyopathy or amyloid deposits.
- Chest x-ray may show evidence of HF.
- Laboratory findings:
- Elevated biomarkers such as NT-proBNP and troponins can be seen in cardiac involvement.
- Genetic testing can confirm the diagnosis of hATTR-CM.
Red Flag Symptoms for hATTR-CM:
- Persistent bilateral CTS, spinal stenosis, and trigger fingers should raise suspicion of hATTR-CM, especially in patients with unexplained HF or arrhythmias.
- A history of family members with similar symptoms or genetic mutations associated with ATTR-CM further supports the diagnosis.
Early recognition of these symptoms is essential for timely diagnosis and intervention in patients with ATTR-CM.
Advertisement
Related to this article

Stress led all triggers, and a sense of an impending attack was the most reliable prodrome in patients with HAE-C1INH in the US HAEA Scientific Registry.

Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).

Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.

The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.

Approval covers patients aged ≥2 years with frequently relapsing or steroid dependent disease in complete remission.

As the FDA weighs its first psychedelic approval, Sarah Norman, MPP, says training, credentialing, and reimbursement are lagging while patients are already asking.

Pranav Garimella discusses what a potential USPSTF kidney screening recommendation could mean for high-risk adults and primary care.
Advertisement
Advertisement
Trending on HCPLive
1
The Case for Routine Kidney Screening, With Pranav Garimella, MBBS, MPH
2
FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome
3
Zilurgisertib Receives FDA Approval for FOP in Patients 12 and Older
4
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
5

